Oncology Drug Reference Sheet: Pafolacianine

An optical imaging agent shown to improve diagnostic accuracy, pafolacianine (Cytalux^™) was approved on November 29, 2021, for use in adult patients with known or suspected ovarian cancer as adjunct therapy in conjunction with planned intraoperative identification of malignant lesions. Pafolacianine is used in combination with a near-infrared (NIR) fluorescence imaging system that requires specialized training provided by the device manufacturer.